Noah Doyle Net Worth

The estimated Net Worth of Noah Doyle is at least $7.02 Million dollars as of 12 March 2020. Noah Doyle owns over 500,000 units of Ritter Pharmaceuticals stock worth over $6,906,844 and over the last 9 years Noah sold RTTR stock worth over $110,000.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Noah Doyle RTTR stock SEC Form 4 insiders trading

Noah has made over 3 trades of the Ritter Pharmaceuticals stock since 2015, according to the Form 4 filled with the SEC. Most recently Noah sold 500,000 units of RTTR stock worth $110,000 on 12 March 2020.

The largest trade Noah's ever made was buying 800,000 units of Ritter Pharmaceuticals stock on 24 June 2015 worth over $4,000,000. On average, Noah trades about 225,000 units every 215 days since 2015. As of 12 March 2020 Noah still owns at least 704,780 units of Ritter Pharmaceuticals stock.

You can see the complete history of Noah Doyle stock trades at the bottom of the page.

What's Noah Doyle's mailing address?

Noah's mailing address filed with the SEC is 1880 Century Park E #1000, Los Angeles, CA 90067, USA.

Insiders trading at Ritter Pharmaceuticals

Over the last 9 years, insiders at Ritter Pharmaceuticals have traded over $124,250 worth of Ritter Pharmaceuticals stock and bought 1,819,751 units worth $8,518,572 . The most active insiders traders include Noah Doyle, Venture Partners, L.P. Javelin, and Matthew W Foehr. On average, Ritter Pharmaceuticals executives and independent directors trade stock every 86 days with the average trade being worth of $1,400,057. The most recent stock trade was executed by Noah Doyle on 12 March 2020, trading 500,000 units of RTTR stock currently worth $110,000.

What does Ritter Pharmaceuticals do?

Ritter Pharmaceuticals, Inc. engages in the development of novel therapeutic products which modulate the human gut microbiome to treat digestive disorders and gastrointestinal diseases. It focuses on the development and commercialization of RP-G28. The company was founded by Andrew J. Ritter and Ira E. Ritter on March 29, 2004 and is headquartered in Los Angeles, CA.

Complete history of Noah Doyle stock trades at Ritter Pharmaceuticals

Ritter Pharmaceuticals executives and stock owners

Ritter Pharmaceuticals executives and other stock owners filed with the SEC include:

• Ira Ritter,
  Director
• Amy Broidrick,
  Independent Director
• Kurt Kruger,
  Independent Director
• Matthew Korenberg,
  Independent Director
• Richard David,
  Independent Director
• Shishir Sinha,
  Vice President - Operations
• Wajdi Abdul-Ahad,
  Chief Scientific Officer, Vice President - Research & Development
• Christopher Lotz,
  Chief Financial Officer, Vice President - Finance
• Michael Poirier,
  Chairman of the Board, President, Chief Executive Officer
• Paul V Maier,
  Director
• Michael D Step,
  CEO
• William M. Merino,
  Director
• Ellen F. Mochizuki,
  VP, Finance
• Partners Llc Stonehenge,
  10% owner
• Matthew W Foehr,
  Director
• Gerald T Proehl,
  Director
• Venture Partners, L.P. Javelin,
  10% owner
• Andrew J Ritter,
  CEO and President
• Noah Doyle,
  Director
• Jeffrey S Benjamin,
  VP of Finance
• John W Beck,
  Chief Financial Officer
• Venture Partners I Spv I, L...,
  10% owner